<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03909750</url>
  </required_header>
  <id_info>
    <org_study_id>GARM 2 Lung</org_study_id>
    <nct_id>NCT03909750</nct_id>
  </id_info>
  <brief_title>Use of Autologous Stem/Stromal Cells In Chronic Lung Disorders: Obstructive (COPD) &amp; Restrictive (RLD)</brief_title>
  <acronym>cSVF-Lung</acronym>
  <official_title>Use of Autologous Stem/Stromal Cells in Chronic Lung Disorders: Obstructive (COPD) and Restrictive (RLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healeon Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Robert W. Alexander, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Healeon Medical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary Disorders are often categorized as Obstructive or Restrictive disorders. This study&#xD;
      will establish two channels of investigation, one group within each type of pulmonary&#xD;
      dysfunction. State-of-the-Art Objective analytics will be employed to track patients from&#xD;
      baseline and 6 month intervals for up to one year.&#xD;
&#xD;
      Chronic Obstructive Pulmonary Disease (COPD) is a lung-related disorder that is characterized&#xD;
      by long-term, often progressive state of poor airflow. Primary symptoms include low oxygen&#xD;
      tension, shortness of breath, productive cough, and broncho-pulmonary inflammation and&#xD;
      interference with oxygen-carbon dioxide exchange. COPD is generally considered those who are&#xD;
      able to better inspire air than to expel. Restrictive lung dysfunctions are generally&#xD;
      considered those who are unable to achieve full inspiration function. Both can create some of&#xD;
      the same symptoms, low Oxygen exchange, activity intolerance of exertion, shortness of breath&#xD;
      (SOB), Pulmonary Hypertension, Loss of lung structure, Pneumothorax (in emphysema), may&#xD;
      mandate supplemental Oxygen therapy, failure of airway mucus management (chronic bronchitis,&#xD;
      bronchiectasis, etc), and other failure of lung function issues.&#xD;
&#xD;
      Restrictive lung disorders represent a group of pulmonary function losses which are due to&#xD;
      acquired fibrosis, congenital fibrotic disorders, functional airway damage (scarring),&#xD;
      vascular abnormalities in arterial/venous supply,&#xD;
&#xD;
      Air pollution and tobacco smoking, chemical inhalation damage, etc. are felt to be common&#xD;
      contributor of these issues. Diagnostic testing is based on poor airflow measured by lung&#xD;
      function studies and whose symptoms do not improve much with anti-asthma bronchodilators,&#xD;
      steroids, and a variety of combination of topical medications.&#xD;
&#xD;
      Study is an interventional study to document the safety and efficacy of use of cSVF in&#xD;
      chronic broncho-pulmonary disease within both groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary Disorders, including both COPD &amp; Restrictive Lung Disease (RLD) are often treated&#xD;
      by limiting exposure to poor air quality, but there is no cure at this time. Most commonly,&#xD;
      the patients are treated upon exacerbations, usually with some combination of inhalers,&#xD;
      steroids, and medications which have proven to be ineffective other than addressing symptoms&#xD;
      and trying to return to baseline symptom help. In addition, many attempted efforts are aimed&#xD;
      at environmental changes, therapy include smoking cessation, vaccinations, respiratory&#xD;
      rehabilitation, and attempts of use of bronchodilators and topical and systemic steroids.&#xD;
      Many must resort to supplemental oxygen therapy, lung transplantation, and antibiotic&#xD;
      supportive therapy during exacerbations.&#xD;
&#xD;
      As of 2013, COPD involve approximately 5% of the global populations (approximately 330&#xD;
      million). Most commonly it occurs approximately equally between men/women and result in about&#xD;
      3 million deaths per year. Estimates of economic costs are estimated to be more than 2.1&#xD;
      trillion dollars in 2010.&#xD;
&#xD;
      This study includes microcannula harvesting of subdermal adipose tissues, incubation,&#xD;
      digestion and isolation of AD-cSVF. This stromal cellular pellet (without actual&#xD;
      extracellular matrix or stromal elements) is then suspended in 500 cc sterile Normal Saline&#xD;
      (NS) and deployed via peripheral intravenous route. Evaluations of safety issues are measured&#xD;
      at intervals (both severe and non-severe categories) and by repeated pulmonary function&#xD;
      studies.&#xD;
&#xD;
      Most pulmonary function tests are, at best some help, but there is now a remarkable testing&#xD;
      that is substantially more informative than standard flow measurements, as they include&#xD;
      extensive anatomical and functional insights using High Resolution Computerized Tomography&#xD;
      (HRCT) Lung. This protocol allows for direct evidence of the air trapping, lung volume&#xD;
      capabilities, and three dimensional imaging of the airways and lungs themselves. This&#xD;
      modality will be the primary comparative between baseline and 6 month post-therapy in&#xD;
      determination of the status and changes than can be demonstrated following use of cellular&#xD;
      stromal vascular fraction (cSVF). After isolation and concentration of the stem/stromal cells&#xD;
      via digestive processing, deployment of such cellular elements are believed to engraft within&#xD;
      the lung capillary tissues. Engraftment is not currently believed to be the primary elements&#xD;
      following parenteral (IV) placement. Rather, it is believed to represent the paracrine&#xD;
      secretory and communication between cell-to-cell or cell-to-matrix which communicates via&#xD;
      exosomal and microvesicular contents that are released to influence the local niche&#xD;
      (microenvironment). Via transfer of microRNA (mRNA) or mitoRNA (miRNA), stem cells are able&#xD;
      to help other pulmonary cells replace or repair damaged elements associated with lung&#xD;
      disorders. Further, these secretions and growth factor/cytokines availability have a positive&#xD;
      influence on the small capillaries within the lung parenchyma, thereby likely to improve the&#xD;
      gas exchange function within the lungs.&#xD;
&#xD;
      Tracking of oxygen saturation (at rest and activity), use of inhalers or other rescue effort&#xD;
      reduction, reduction of oxygen supplement, and improved respiratory efforts will be&#xD;
      performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Withdrawn [COVID restrictions prevent patient enrollment or treatment. Clinical Trial facility&#xD;
    is being closed due to viral limitations and loss of staff to perform]&#xD;
  </why_stopped>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety-Pulmonary Function: occurrence or frequency of adverse or severe adverse events during study</measure>
    <time_frame>6 months evaluate function and adverse events</time_frame>
    <description>Pulmonary Function as occurrence or frequency of adverse or severe adverse events during study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High Resolution Computerized Tomography - Lungs Fluidda Analysis</measure>
    <time_frame>Baseline and 6 month Comparative Study</time_frame>
    <description>Fluidda Pulmonary Objective Analytics</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COPD</condition>
  <condition>Respiratory Insufficiency</condition>
  <arm_group>
    <arm_group_label>Lipoaspiration Microcannula ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isolation-Concentration Adipose cSVF ARM 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline IV ARM 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sterile Normal Saline IV with cSVF</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lipoaspiration</intervention_name>
    <description>Close syringe microcannula harvesting subdermal fat and perivascular stem/stromal cells</description>
    <arm_group_label>Lipoaspiration Microcannula ARM 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>AD-cSVF</intervention_name>
    <description>Isolation of AD-cSVF</description>
    <arm_group_label>Isolation-Concentration Adipose cSVF ARM 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normal Saline IV</intervention_name>
    <description>Normal Saline IV containing AD-cSVF</description>
    <arm_group_label>Normal Saline IV ARM 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented COPD or RLD by qualified Medical Provider&#xD;
&#xD;
          -  History of Pulmonary Function Deficits or supplemental oxygen therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cancer of the Lung&#xD;
&#xD;
          -  Patient's on chemotherapy or radiation for Cancer (or History within 5 years)&#xD;
&#xD;
          -  Inability to comply with Baseline and 6 month post-treatment HDCT lungs&#xD;
&#xD;
          -  General health or inability or unwillingness or ability to provide informed consent&#xD;
             for study&#xD;
&#xD;
          -  History of lung transplantation&#xD;
&#xD;
          -  Life expectancy of &lt;3 months due to concomitant illnesses&#xD;
&#xD;
          -  Exposure to any investigational drug of procedure within 1 month prior to study&#xD;
             enrollment which may interfere with interpretation of outcomes&#xD;
&#xD;
          -  Illness which, in investigator's judgement, may interfere with patient's ability of&#xD;
             comply with protocol, compromise patient safety, ability to provide informed consent&#xD;
             or interfere with the interpretation of study outcomes.&#xD;
&#xD;
          -  Subjects with chronic immunosuppressive or chemotherapeutic medication.&#xD;
&#xD;
          -  Known drug or alcohol dependence or other factors which may interfere with study&#xD;
             conduct or interpretation of result in opinion of investigators.&#xD;
&#xD;
          -  Subjects with documented Alpha 2 Antitrypsin Deficiency (inherited lung and liver&#xD;
             disorder)&#xD;
&#xD;
          -  Patient with history of Hepatitis (except Hepatitis A history)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn C Terry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Global Alliance for Regenerative Medicine (GARM-HN)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Global Alliance for Regenerative Medicine-USA</name>
      <address>
        <city>Stevensville</city>
        <state>Montana</state>
        <zip>59870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Alliance of Regenerative Medicine (GARM) International</name>
      <address>
        <city>Roatan</city>
        <state>Hn</state>
        <zip>Honduras</zip>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Honduras</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012 Apr 7;379(9823):1341-51. doi: 10.1016/S0140-6736(11)60968-9. Epub 2012 Feb 6. Review.</citation>
    <PMID>22314182</PMID>
  </results_reference>
  <results_reference>
    <citation>Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. Epub 2007 May 16. Review.</citation>
    <PMID>17507545</PMID>
  </results_reference>
  <results_reference>
    <citation>Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442.</citation>
    <PMID>17132052</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahler DA. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006 May;3(3):234-8. Review.</citation>
    <PMID>16636091</PMID>
  </results_reference>
  <results_reference>
    <citation>Holland AE, Hill CJ, Jones AY, McDonald CF. Breathing exercises for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Oct 17;10:CD008250. doi: 10.1002/14651858.CD008250.pub2. Review.</citation>
    <PMID>23076942</PMID>
  </results_reference>
  <results_reference>
    <citation>Kennedy SM, Chambers R, Du W, Dimich-Ward H. Environmental and occupational exposures: do they affect chronic obstructive pulmonary disease differently in women and men? Proc Am Thorac Soc. 2007 Dec;4(8):692-4. Review.</citation>
    <PMID>18073405</PMID>
  </results_reference>
  <results_reference>
    <citation>Devereux G. ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors. BMJ. 2006 May 13;332(7550):1142-4. Review.</citation>
    <PMID>16690673</PMID>
  </results_reference>
  <results_reference>
    <citation>Foreman MG, Campos M, Celedón JC. Genes and chronic obstructive pulmonary disease. Med Clin North Am. 2012 Jul;96(4):699-711. doi: 10.1016/j.mcna.2012.02.006. Epub 2012 Mar 6. Review.</citation>
    <PMID>22793939</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006 Apr;3(2):180-4. Review.</citation>
    <PMID>16565429</PMID>
  </results_reference>
  <results_reference>
    <citation>Mackay AJ, Hurst JR. COPD exacerbations: causes, prevention, and treatment. Med Clin North Am. 2012 Jul;96(4):789-809. doi: 10.1016/j.mcna.2012.02.008. Epub 2012 Mar 16. Review.</citation>
    <PMID>22793945</PMID>
  </results_reference>
  <results_reference>
    <citation>Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD005305. doi: 10.1002/14651858.CD005305.pub3. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 08;12 :CD005305.</citation>
    <PMID>21975749</PMID>
  </results_reference>
  <results_reference>
    <citation>Saxena A, Watkin SW. Bilateral malignant testicular carcinoid. Br J Urol. 1990 Mar;65(3):302-3.</citation>
    <PMID>2337756</PMID>
  </results_reference>
  <results_reference>
    <citation>Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Mar 10;(3):CD010115. doi: 10.1002/14651858.CD010115.pub2. Review.</citation>
    <PMID>24615270</PMID>
  </results_reference>
  <results_reference>
    <citation>COPD Working Group. Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12(7):1-64. Epub 2012 Mar 1. Review.</citation>
    <PMID>23074435</PMID>
  </results_reference>
  <results_reference>
    <citation>Bradley JM, O'Neill B. Short-term ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004356. Review.</citation>
    <PMID>16235359</PMID>
  </results_reference>
  <results_reference>
    <citation>Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Dec 12;12:CD010257. doi: 10.1002/14651858.CD010257. Review. Update in: Cochrane Database Syst Rev. 2018 Oct 29;10:CD010257.</citation>
    <PMID>23235687</PMID>
  </results_reference>
  <results_reference>
    <citation>Inamdar AC, Inamdar AA. Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell. Exp Lung Res. 2013 Oct;39(8):315-27. doi: 10.3109/01902148.2013.816803. Epub 2013 Aug 30. Review.</citation>
    <PMID>23992090</PMID>
  </results_reference>
  <results_reference>
    <citation>Conese M, Piro D, Carbone A, Castellani S, Di Gioia S. Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases: role of plasticity and heterogeneity. ScientificWorldJournal. 2014 Jan 19;2014:859817. doi: 10.1155/2014/859817. eCollection 2014. Review.</citation>
    <PMID>24563632</PMID>
  </results_reference>
  <results_reference>
    <citation>McQualter JL, Anthony D, Bozinovski S, Prêle CM, Laurent GJ. Harnessing the potential of lung stem cells for regenerative medicine. Int J Biochem Cell Biol. 2014 Nov;56:82-91. doi: 10.1016/j.biocel.2014.10.012. Epub 2014 Oct 15. Review.</citation>
    <PMID>25450456</PMID>
  </results_reference>
  <results_reference>
    <citation>Tzouvelekis A, Ntolios P, Bouros D. Stem cell treatment for chronic lung diseases. Respiration. 2013;85(3):179-92. doi: 10.1159/000346525. Epub 2013 Jan 29. Review. Erratum in: Respiration. 2013;86(4):294.</citation>
    <PMID>23364286</PMID>
  </results_reference>
  <results_reference>
    <citation>Tzouvelekis A, Laurent G, Bouros D. Stem cell therapy in chronic obstructive pulmonary disease. Seeking the Prometheus effect. Curr Drug Targets. 2013 Feb;14(2):246-52. Review.</citation>
    <PMID>23256721</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

